Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

This study tests a combination of two investigational vaccines (IO102-IO103) together with the immunotherapy drug pembrolizumab (Keytruda) given before and after surgery for patients with resectable (operable) stage III melanoma or advanced head and neck cancer. The goal is to boost the immune system's ability to fight remaining cancer cells after surgery. **You may be eligible if...** - You are 18 or older with stage III melanoma that can be surgically removed, OR with advanced head and neck cancer (certain types) that is suitable for surgery - You have not received any prior treatment for this specific tumor - Your overall health is good (ECOG performance status 0 or 1) **You may NOT be eligible if...** - You have uveal, mucosal, or acral melanoma, or melanoma that has spread to distant organs - You have a history of severe immune-related side effects from prior immunotherapy - You have active autoimmune disease, immune deficiency, or require systemic steroids - You are pregnant or breastfeeding - You have had an organ transplant Talk to your doctor to see if this trial is right for you.